Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors. The presentation covered experimental results that corroborated clinical biomarker data from patients with advanced solid tumor cancers treated in a Phase 1 trial with TPST-1120 showing increased expression of select immune-related genes and elevated plasma Free Fatty Acid (FFA) levels associated with clinical response. TPST-1120 is an oral, selective PPAR⍺ antagonist in clinical development that has shown promising results, including positive data from a randomized study in first-line hepatocellular carcinoma (HCC) patients compared to the standard of care.
加利福尼亞州布里斯班，2024年3月12日（GLOBE NEWSWIRE）——Tempest Therapeutics, Inc.（納斯達克股票代碼：TPST），一家處於臨床階段的生物技術公司，正在開發同類首創的生物技術公司我 抗癌的靶向和免疫介導療法今天宣佈了在癌症免疫療法協會（SITC）2024年春季科學會議上發佈的海報演講，重點介紹了臨床前數據，這些數據顯示單獨使用 TPST-1120 或使用免疫檢查點抑制劑治療的幾種癌症模型具有強大的抗腫瘤活性。該演講涵蓋了實驗結果，這些結果證實了在 1 期試驗中使用 TPST-1120 治療的晚期實體瘤癌患者的臨床生物標誌物數據，顯示特定免疫相關基因的表達增加，血漿遊離脂肪酸 (FFA) 水平升高與臨床反應有關。TPST-1120 是臨床開發中的口服選擇性 PPAR拮抗劑，已顯示出令人鼓舞的結果，包括一項針對一線肝細胞癌 (HCC) 患者的隨機研究得出的與標準護理相比的陽性數據。
"Data presented at the SITC Spring Scientific Meeting bolster our mechanistic understanding of PPARα blockade in cancer patients and reinforce a basis for the ongoing late-stage clinical development of TPST-1120," said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest. "Based on positive Phase 1 and 2 data, we are planning a pivotal study in patients with first-line liver cancer, and we also look forward to evaluating the potential of TPST-1120 in additional cancer indications."
Tempest首席醫學官兼研發主管山姆·惠廷博士說：“在SITC春季科學會議上公佈的數據增強了我們對癌症患者PPARα阻斷的機制理解，也爲正在進行的 TPST-1120 後期臨床開發奠定了基礎。”“根據陽性的 1 期和 2 期數據，我們正計劃對一線肝癌患者進行一項關鍵研究，我們還期待評估 TPST-1120 在其他癌症適應症中的潛力。”
In preclinical models of liver, colon and pancreatic cancer, TPST-1120 elicited a greater than 50% inhibition of tumor growth with enhanced inhibition observed in liver and colon cancer models when co-administered with anti-PD-1. In addition, biomarker results from the Phase 1 clinical trial of TPST-1120 in multiple solid tumor indications showed statistically significant, exposure-dependent elevations in expression levels of multiple immune-related genes, and patients exhibiting objective responses displayed increased circulating free fatty acids (FFA), both of which are in-line with the proposed TPST-1120 mechanism of action. Clinical response and biomarker findings support that inhibition of PPARα may be an effective therapeutic strategy for the treatment of cancer.
在肝癌、結腸癌和胰腺癌的臨床前模型中，與抗 PD-1 聯合使用時，TPST-1120 可抑制腫瘤生長超過 50%，在肝癌和結腸癌模型中觀察到增強的抑制作用。此外，針對多種實體瘤適應症的 TPST-1120 1 期臨床試驗的生物標誌物結果顯示，多個免疫相關基因的表達水平具有統計學意義的暴露依賴性升高，表現出客觀反應的患者表現出循環遊離脂肪酸 (FFA) 增加，兩者均符合擬議的 TPST-1120 作用機制。臨床反應和生物標誌物發現支持，抑制PPARα可能是治療癌症的有效治療策略。
These findings complement positive data reported in October 2023 from a global randomized phase 1b/2 study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC. The differentiating data showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations when compared to atezolizumab and bevacizumab alone, the standard of care in first-line HCC.
這些發現補充了 2023 年 10 月報告的 TPST-1120 與阿替珠單抗和貝伐珠單抗聯合用於晚期 HCC 患者的 1b/2 期全球隨機 1b/2 期研究的陽性數據。差異化數據顯示，與單獨使用阿替珠單抗和貝伐珠單抗（一線肝癌的護理標準）相比，TPST-1120 組在多個研究終點和相關生物標誌物定義的患者亞群中具有臨床優勢。
About TPST-1120
關於 TPST-1120
TPST-1120 is an oral, small molecule, selective PPAR⍺ antagonist. Tempest's data suggest that TPST-1120 treats cancer by targeting tumor cell metabolism directly, as well as by modulating immune suppressive cells and angiogenesis in the tumor microenvironment. In a Phase 1 clinical trial in patients with heavily-pretreated advanced solid tumors, TPST-1120 as monotherapy and in combination with the PD-1 inhibitor nivolumab demonstrated tumor reduction (including RECIST responses) and biomarker modulation. In a global randomized phase 1b/2 study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced hepatocellular carcinoma (HCC), the TPST-1120 arm showed clinical superiority across multiple study endpoints when compared to atezolizumab and bevacizumab alone, the standard of care. TPST-1120 is wholly-owned by Tempest.
TPST-1120 是一種口服、小分子、選擇性的 PPAR拮抗劑。Tempest 的數據表明，TPST-1120 通過直接靶向腫瘤細胞代謝，以及調節腫瘤微環境中的免疫抑制細胞和血管生成來治療癌症。在一項針對經過大量預處理的晚期實體瘤患者的1期臨床試驗中，TPST-1120 作爲單一療法並與PD-1抑制劑nivolumab聯合使用顯示腫瘤減輕（包括RECIST反應）和生物標誌物調節。在一項針對晚期肝細胞癌（HCC）一線患者的 TPST-1120 聯合阿替珠單抗和貝伐珠單抗的全球隨機1b/2期研究中，與單獨的阿替珠單抗和貝伐珠單抗相比，TPST-1120 組在多個研究終點上顯示出臨床優勢，這是一種護理標準。TPST-1120 由 Tempest 全資擁有。
About Tempest Therapeutics
關於《暴風雨》
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at .
Tempest Therapeutics是一家處於臨床階段的生物技術公司，正在推進多元化的小分子候選產品組合，這些候選產品包含腫瘤靶向和/或免疫介導的機制，有可能治療各種腫瘤。該公司的新項目包括針對一線癌症患者的隨機全球研究的早期研究到後期研究。Tempest 總部位於加利福尼亞州布里斯班。有關 Tempest 的更多信息可以在該公司的網站上找到 。
Investor & Media Contacts
投資者和媒體聯繫人
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
西爾維亞·惠勒
惠爾豪斯生命科學顧問
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Aljanae Reynolds
惠爾豪斯生命科學顧問
areynolds@wheelhouselsa.com
i If approved by the FDA
我 如果獲得美國食品和藥物管理局的批准
譯文內容由第三人軟體翻譯。